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Purpose: Over the last 30 years, Serratia marcescens (S. marcescens) has emerged 
as an important pathogen, and a common cause of nosocomial infections. The aim 
of this study was to identify risk factors associated with mortality in patients with 
S. marcescens bacteremia. Materials and Methods: We performed a retrospective 
cohort study of 98 patients who had one or more blood cultures positive for S. 
marcescens between January 2006 and December 2012 in a tertiary care hospital 
in Seoul, South Korea. Multiple risk factors were compared with association with 
28-day all-cause mortality. Results: The 28-day mortality was 22.4% (22/98 epi-
sodes). In a univariate analysis, the onset of bacteremia during the intensive care 
unit stay (p=0.020), serum albumin level (p=0.011), serum C-reactive protein level 
(p=0.041), presence of indwelling urinary catheter (p=0.023), and Sequential Oran 
Failure Assessment (SOFA) score at the onset of bacteremia (p<0.001) were sig-
nificantly different between patients in the fatal and non-fatal groups. In a multi-
variate analysis, lower serum albumin level and an elevated SOFA score were in-
dependently associated with 28-day mortality [adjusted odds ratio (OR) 0.206, 
95% confidential interval (CI) 0.044‒0.960, p=0.040, and adjusted OR 1.474, 95% 
CI 1.200‒1.810, p<0.001, respectively]. Conclusion: Lower serum albumin level 
and an elevated SOFA score were significantly associated with adverse outcomes 
in patients with S. marcescens bacteremia.
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INTRODUCTION
Serratia marcescens (S. marcescens) is a Gram-negative Enterobacteriaceae spe-
cies, initially considered non-pathogenic due to its low virulence in healthy popu-
lations.1 Over the last 30 years, however, this species has emerged as an important 
pathogen, and a common cause of nosocomial infections.2 S. marcescens has been 
shown to cause a wide range of infectious diseases, including urinary, respiratory, 
and biliary tract infections, peritonitis, wound infections, and intravenous catheter-
related infections, which can also lead to life-threatening bacteremia.1,2 Risk fac-
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ples obtained from a patient, combined with clinical symp-
toms compatible with systemic inflammatory response syn-
drome.15 Hospital-acquired bacteremia was defined as a 
positive blood culture taken from a patient no sooner than 
48 h after hospital admission, whereas healthcare-associat-
ed bacteremia was defined as a positive blood culture taken 
from a patient receiving home and/or ambulatory intrave-
nous therapy, hemodialysis, wound care, chemotherapy, or 
nursing care, or who had attended a hospital clinic within 
the last 30 days; patients hospitalized in an acute care hos-
pital for ≥2 days within the last 90 days; or those living in a 
nursing home or long-term care facility.16 The primary site 
of infection was presumed to be the source of bacteremia if 
S. marcescens was identified from any culture specimens at 
the time of bacteremia onset; if S. marcescens was not iden-
tified from any culture other than the blood, the source was 
presumed to be primary bacteremia. Polymicrobial bactere-
mia was defined as bacteremia where more than one organ-
ism were isolated from the same blood culture specimen. 
Septic shock was defined as sepsis-induced organ hypo-per-
fusion, combined with either a systolic blood pressure <90 
mm Hg or <40 mm Hg less than baseline, or a mean arteri-
al pressure <65 mm Hg after a fluid resuscitation, eventual-
ly leading to require the vasopressor use.17 Underlying 
chronic diseases included hemato-oncological disease, 
chronic renal disease, chronic liver disease, chronic lung 
disease, cardiovascular disease, and cerebrovascular dis-
ease, as defined by the International Classification of Dis-
ease, 10th Revision.18 Prior use of antimicrobial agent was 
defined as receipt for at least 48 h within 1 month prior to 
the bacteremic episode. Appropriateness of initial empirical 
antimicrobial agents was defined as the use of at least one 
in vitro susceptible antimicrobial agent within 24 h of posi-
tive blood culture before the susceptibility was known.19 
Definitive therapy was defined as antibiotic therapy given 
properly according to the results of final blood culture.20 
Hypoalbuminemia was defined as a serum albumin of less 
than 3.0 g/dL at the time of bacteremia.21,22 Twenty-eight-
day all-cause mortality was investigated to confirm the pri-
mary outcome. 
Microbiological tests
Clinical isolates were evaluated using either conventional 
techniques or the ATB 32 GN system (bioMérieux, Marcy 
l’ Etoile, France). Antimicrobial susceptibility testing was 
performed by microbiology laboratory staff using the disk-
diffusion method or a VITEK-2 N131 card (bioMérieux, 
tors associated with these infections include prolonged im-
munosuppressive therapy, previous antimicrobial agents, 
indwelling catheterization, and underlying diseases such as 
chronic pulmonary disease and diabetes mellitus.3 
Recent epidemiologic analyses have shown an increase 
in the rate of antimicrobial resistance among S. marcescens 
isolates.4-6 Furthermore, multidrug-resistant (MDR) strains 
of S. marcescens have been associated with serious out-
comes.7-9 The overall mortality rate of S. marcescens bacte-
remia remains high, ranging from 25‒58%.2,9,10 However, 
despite this high mortality rate, the risk factors associated 
with mortality in S. marcescens bacteremia have not been 
well established since 2008 regardless of MDR strains.10-13
Therefore, we aimed to identify the risk factors associat-
ed with mortality in patients with S. marcescens bacteremia 
during the last 6 years. 
MATERIALS AND METHODS
Study population and design 
A retrospective cohort study was conducted to investigate 
risk factors associated with mortality in S. marcescens bac-
teremia at Severance Hospital, a 2000-bed, tertiary-care 
teaching hospital, Seoul, South Korea. Inclusion criteria for 
this study included patients with 18 years of age or older, 
identified as having one or more blood cultures positive for 
S. marcescens between January 2006 and December 2012. 
For subjects reporting more than one episode of S. marces-
cens bacteremia, only the first episode was accepted. De-
mographic and clinical variables were evaluated using mi-
crobiological laboratory records and clinical data gained 
from electronic medical records; these included age, gen-
der, length of hospital stay, underlying diseases, predispos-
ing conditions, portal of entry, appropriateness of antimi-
crobial agents, appropriateness of definitive therapy, results 
of antimicrobial susceptibility testing, laboratory data at the 
time of bacteremia onset, Sequential Organ Failure Assess-
ment score (SOFA),14 and 28-day all-cause mortality. This 
study was approved by our Institutional Review Board. In-
formed consent was exempt from our local ethics committee 
because this study was concerned to cause minimal harm on 
persons.
Definitions
Significant S. marcescens bacteremia was defined as S. 
marcescens isolates cultured from one or more blood sam-
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and underlying conditions of all patients with S. marces-
cens bacteremia. Sixty patients (61.2%) were male, and the 
ages of patients ranged from 26 to 92 years (median age, 
63.5 years). Of 98 bacteremic episodes, hospital-acquired 
bacteremia accounted for 73.5% of the episodes (72 pa-
tients), whereas healthcare-associated bacteremia account-
ed for 18.4% of the episodes (18 patients). The remaining 8 
episodes (8.1%) were defined as community-acquired bac-
teremia. The most common underlying condition was ma-
lignancy (46.9%), which included conditions such as solid 
organ and hematologic malignancy; and diabetes mellitus 
(30.6%) were also common. The most frequent portal of en-
try was the lower respiratory tract (50%). Other portals of 
entry included the urinary tract (20.4%), abdomen (11.2%), 
skin and soft tissue (10.2%), and intra-venous catheter 
(5.1%). Half of the patients had central venous catheters 
(CVCs), including chemo-ports, and urinary catheters. 
56.1% of the patients showed bacteremia during the inten-
sive care unit (ICU) stay. Among them, the fatal group 
showed a greater incidence of bacteremia during the ICU 
stay (77.3%) than the non-fatal group (50%) (p=0.020). 
46.9% of the episodes (46 patients) showed the 3rd cepha-
losporin resistance, but there was no statistically significant 
difference between the fatal and non-fatal group (p=0.744). 
Antimicrobial susceptibilities
The antimicrobial susceptibilities of S. marcescens clinical 
isolates are characterized in Fig. 2. The majority of isolates 
were susceptible to ertapenem (100%), meropenem (99%), 
imipenem (93.4%), cefepime (87.8%), isepacin (81.8%), and 
ceftazidime (76.5%). A few isolates exhibited susceptibility 
to amoxicillin/clavulanic acid (1.1%), ampicillin (2.1%), and 
ampicillin/sulbactam (1.7%). 
Risk factors for 28-day all-cause mortality 
The 28-day all-cause mortality was 22.4% (22/98). Univari-
ate analysis revealed significant differences in the number of 
important clinical covariates including the onset of bactere-
mia during the ICU stay (p=0.020), serum albumin level 
(p=0.011), serum C-reactive protein level (p=0.041), pres-
ence of indwelling urinary catheter (p=0.023), and SOFA 
score at the onset of bacteremia (p<0.001) between patients 
in the fatal and non-fatal groups (Table 1). In a multivariate 
analysis, lower serum albumin level [adjusted odds ratio 
(OR) 0.206, 95% confidential interval (CI) 0.044‒0.960, 
p=0.040], and elevated SOFA score (adjusted OR 1.474, 
95% CI 1.200‒1.810, p<0.001) were all found to be inde-
Hazelwood, MO, USA). Results were interpreted using the 
guidelines set forth by the Clinical and Laboratory Stan-
dards Institute.23
Statistical analyses 
Student’s t-test was used to compare continuous variables; 
and categorical variables were analyzed using either a χ2 or 
Fisher’s exact test as appropriate. Nonparametric variables 
were analyzed using the Mann-Whitney U test. Univariate 
and multivariate analyses to evaluate independent risk fac-
tors for all-cause mortality in S. marcescens bacteremia 
were performed through the logistic regression models. Sta-
tistical analyses were performed using the SPSS software, 
version 20 (SPSS Inc., Chicago, IL, USA). p-values <0.05 
were considered to indicate statistical significance; all val-
ues reported are for two-tailed analyses.
RESULTS
 
Epidemiology of S. marcescens bacteremia
A total of 98 episodes of S. marcescens bacteremia were 
identified between January 2006 and December 2012. The 
annual distribution of S. marcescens bacteremia is shown in 
Fig. 1. To confirm the outbreak, the trend was investigated 
and stratified by ward and period, but there were no out-
breaks. 
Characteristics of patients with S. marcescens 
bacteremia
Table 1 shows the demographics, clinical characteristics, 
Fig. 1. Annual distribution of S. marcescens bacteremia in Severance 
Hospital between January 2006 and December 2012.
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Table 1. Clinical Characteristics of the Patients with Serratia marcescens Bacteremia
Characteristics Total cases (n=98)
Fatal group 
(n=22)
Non-fatal group 
(n=76) p value
Age, yr, median (range)      63 (26‒92)   62.5 (26‒92)        63 (26‒88) 0.692
Age >65 yrs, n (%)      46 (46.9)      10 (45.5)        36 (47.4) 0.871
Male, n (%)      60 (61.2)      10 (50)        50 (64.1) 0.253
BMI (kg/m2) 22.36 (12.17‒40.09) 21.77 (12.17‒40.09)   23.27 (14.79‒33.42) 0.139
Polymicrobial, n (%)      27 (27.6)        5 (22.7)        22 (28.9) 0.573
Acquisition of bacteremia, n (%) 0.651
    Hospital-acquired      72 (73.5 )      18 (81.8)        54 (71.1)
    Healthcare-associated      18 (18.4)        3 (13.6)        15 (19.7)
    Community-acquired        8 (8.1)        1 (4.5)          7 (9.2)
Underlying diseases, n (%) 
    Malignancy 
    Solid organ malignanacy      36 (36.7)      11 (50)        25 (32.9) 0.144
    Hematologic malignancy      10 (10.2)        1 (4.5)          9 (11.8) 0.450
    Diabetes mellitus      30 (30.6)        5 (22.7)        25 (32.9) 0.360
    Chronic renal disease      26 (26.5)        4 (18.2)        22 (28.9) 0.308
    Cerebrovascular disease      24 (24.5)        5 (22.7)        19 (25) 0.829
    Cardiovascular disease                                   11 (11.2)        3 (13.6)          8 (10.5) 0.714
    Chronic liver disease        6 (6.1)        3 (13.6)          3 (3.9) 0.132
    Congestive heart failure        5 (5.1)        1 (4.5)          4 (5.3) 1.000
    Neuromuscular disease        5 (5.1)        0 (0)          5 (6.6) 0.592
    Chronic lung disease        4 (4.1)        0 (0)          4 (5.3) 0.571
    Solid organ transplantation        3 (3.1)        1 (4.5)          2 (2.6) 0.540
    Rheumatologic disease        3 (3.1)        0 (0)          3 (3.9) 1.000
Predisposing conditions, n (%)
    Prior anti-biotic use (within 1 month)      49 (50)      11 (50)        38 (50) 1.000 
    Immunosuppressive therapy      19 (19.4)        4 (18.2)        15 (19.7) 1.000
    Inappropriate empirical antimicrobial 
      therapy      17 (17.3)            4 (18.2)          13 (17.1)  1.000
    Inappropriate definitive therapy        3 (3.1)        1 (4.5)            2 (2.6)   0.544
    CVC indwelling      49 (50)      15 (68.2)          34 (44.7) 0.052
    Urinary catheter indwelling      54 (55.1)       17 (77.3)         37 (48.7)  0.023
    Onset of bacteremia during the ICU stay      55 (56.1)        17 (77.3)        38 (50)  0.020
Laboratory data 
    Leukocyte count (×1000/uL) (range)   9.08 (0.45‒60.95)   9.94 (0.45‒60.95)     8.80 (0.71‒51.96) 0.345
    Serum CRP (mg/L) (range) 93.84 (4.19‒346) 76.44 (4.19‒346) 125.01 (12.1‒335) 0.041
    Serum albumin (g/dL) (range)     3.1 (2.0‒4.4)     2.7 (2.0‒4.1)       3.2 (2.1‒4.4) 0.011
SOFA                                                                                          4 (0‒19)         3 (0‒13)        9.5 (3‒19) <0.001
Portal of entry, n (%)
    Lower respiratory tract      49 (50)      14 (63.6)        35 (46.1) 0.152
    Urinary tract      20 (20.4)        4 (21.1)        16 (18.2) 1.000
    Abdomen      11 (11.2)        2 (9.1)          9 (11.8)  1.000
    Skin and soft tissue      10 (10.2)        0 (0)        10 (13.2) 0.110
    Biliary tract infection        5 (5.1)                          2 (9.1)          3 (3.9) 0.314
    Intra-venous catheter        5 (5.1)        1 (4.5)          4 (5.3) 1.000
    Primary bacteremia        4 (5.8)        0 (0)          4 (5.3)          0.572
Presence of 3rd cephalosporin resistance      46 (46.9)      11 (50)        35 (46.1) 0.744 
BMI, body mass index; CRP, C-reactive protein; CVC, central venous catheter; SOFA, Sequential Oran Failure Assessment; ICU, intensive care unit. 
Values are given as n (%) or range.
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years), pneumonia, hemorrhage, shock, inappropriate treat-
ment, leukocytosis (leukocyte count >20000/mm3), throm-
bocytopenia (platelet count <50000/mm3), hyperbilirubine-
mia (serum total bilirubin >18 µmol/L), ICU stay, rapidly 
fatal or ultimately fatal disease, existence of poly-microor-
ganisms, and unknown portal of entry.7,12,29-31 Previous stud-
ies reports have directly investigated the association between 
chronic, fatal conditions and S. marcescens-associated bacte-
remia.12,31 Watanakunakorn reported that both rapidly fatal 
and ultimately fatal diseases influenced the rate of mortality 
in S. marcescens bacteremia-related patients with no under-
lying conditions. Similar results were obtained by Choi, et 
al.12 with rapidly fatal or ultimately fatal diseases serving as 
independent prognostic factors for S. marcescens bactere-
mia-associated fatality. However, in our study, underlying 
diseases were not significantly different between the fatal 
and the non-fatal group. 
Herein, we identified significant associations between 28-
day all-cause mortality and decreased serum albumin, and 
elevated SOFA score. Serum albumin level was significant-
pendent risk factors for mortality in patients with S. marce-
scens bacteremia (Table 2).
DISCUSSION
A number of recent reports have shown that S. marcescens 
bacteremia may arise from both community-acquired as 
well as healthcare-associated exposures.10,12,13,24,25 Further-
more, an increase in the number of multidrug-resistant S. 
marcescens strains has been reported worldwide.26-28 As 
these factors can substantially influence the outcome of S. 
marcescens bacteremia, we sought to identify the risk fac-
tors associated with S. marcescens-related mortality during 
recent 6 years. In our study, the 28-day all-cause mortality 
rate was 22.4%, similar to that in a previous report from 
South Korea.12 
In previous studies, a wide array of independent risk fac-
tors have been found to be associated with mortality in pa-
tients with S. marcescens bacteremia, including old age (>65 
Table 2. Risk Factors for the Mortality in Patients with S. marcescens Bacteremia
Variables OR 95% CI p value
Age 0.964 0.917‒1.014 0.164
ICU stay 0.939 0.140‒6.289 0.950
Serum albumin 0.206 0.044‒0.960 0.040
SOFA 1.474 1.200‒1.810 <0.001
Presence of indwelling urinary catheter 0.886 0.176‒4.447 0.880
Presence of 3rd cephalosporin resistance 0.896  0.211‒3.804 0.882
ICU, intensive care unit; SOFA, Sequential Oran Failure Assessment; OR, odds ratio; CI, confidential interval. 
Multivariate logistic regression analyses were performed with all statistically significant variables of less than 0.05 of p-value obtained from univariate 
analyses. 
Fig. 2. In vitro antibiotic susceptibility tests for S. marcescens isolates cultured from blood.
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conducted in larger patient populations involving multiple 
centers, are necessary to more accurately identify the risk 
factors associated with mortality in S. marcescens bactere-
mia. Finally, the small sample size of those with S. marces-
cens bacteremia may possibly influence our results.
In conclusions, lower serum albumin level and an elevat-
ed SOFA score were significantly associated with adverse 
outcomes in patients with S. marcescens bacteremia. 
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